Wave Life Sciences says GSK selects hepatology siRNA candidate, triggering $12 million milestone payment
WVE•GSK selected a hepatology siRNA candidate under its collaboration with Wave Life Sciences, triggering a $12 million milestone payment to Wave. Wave remains eligible for $330 million to $375 million in development, launch and commercial milestones per program, plus tiered royalties.
1. Candidate selection triggers payment
GSK selected a hepatology siRNA candidate developed with Wave Life Sciences to enter its development pipeline, triggering a $12 million milestone payment to Wave. The candidate uses Wave’s GalNAc-siRNA design.
2. Other programs progressing
Wave remains eligible for $330 million to $375 million in development, launch and commercial milestones per program, as well as tiered royalties. Three additional collaboration programs are progressing toward potential candidate selection.
